Condition: Immune-related Adverse Event · Sponsor: Lucie Heinzerling
This study is an open, monocentric study. It includes patients with irAE refractory to standard therapy or patients where corticosteroids cannot be tapered. Patients will either be treated with ECP or second line immunosuppressive therapy according to investigator's choice. Patients will be followed for 24 weeks after first treatment.
This description comes directly from the study's public registry record.
Lucie Heinzerling · +49 89 4400 56326 · lucie.heinzerling@med.uni-muenchen.de
Dirk Tomsitz · +49 89 4400 56326 · dirk.tomsitz@med.uni-muenchen.de
Always discuss trial participation with your own doctor first.
| LMU Klinikum Hauttumorzentrum | Munich, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05700565